Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lyn Benson who wrote (22615)	6/23/1998 9:42:00 AM
From: Henry Niman	Read Replies (1) of 32384

Lyn, LGND really has a corner on this market. In the designer estrogens they have programs targeting Evista, Droloxifene, CP-366,156, and TSE424. They have also demonstrated Panretin and Targretin synergies with Tamoxifen and Evista in treatment and prevention of breast cancer. Now they are publishing in Progestin mimics that are tissue specific which can also be given in combination with the designer estrogens! However, they also have published on activation of RARs and RXRs by retinoids and rexinoids which cause shape changes in the hormone receptors which have different interations with different tissue specific proteins in the nucleous that regulate gene expression. The specificities will guide future treatment and prevention strategies and LGND is EXTREMELY well positioned.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next